Literature DB >> 3371190

Vancomycin serum protein binding determination by ultrafiltration.

B H Ackerman1, E H Taylor, K M Olsen, W Abdel-Malak, A A Pappas.   

Abstract

Sixty-two serum concentrations were obtained from 12 infected patients enrolled in a vancomycin pharmacokinetic study. Both unbound and total serum vancomycin concentrations were measured using ultrafiltration and a commercial fluorescent polarization immunoassay. Ultrafiltrates were obtained by centrifugation at 1000 X g for ten minutes at room temperature and their assay indicated a range in protein binding from 7.9 to 71 percent. The mean protein binding (mean +/- SD) was 41.95 +/- 14.15 percent. No measurable adsorption of vancomycin onto the ultrafiltration membrane was noted. Orthogonal regression of unbound versus total vancomycin concentrations was described by the equation y = 0.597x-0.362 with a correlation coefficient of 0.948.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3371190     DOI: 10.1177/106002808802200404

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  15 in total

Review 1.  Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing.

Authors:  Jürgen Beer; Claudia Christina Wagner; Markus Zeitlinger
Journal:  AAPS J       Date:  2009-01-01       Impact factor: 4.009

2.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

Authors:  T G Cantú; J D Dick; D E Elliott; R L Humphrey; D M Kornhauser
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 3.  Protein binding: do we ever learn?

Authors:  Markus A Zeitlinger; Hartmut Derendorf; Johan W Mouton; Otto Cars; William A Craig; David Andes; Ursula Theuretzbacher
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

4.  Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.

Authors:  Jill M Butterfield; Nimish Patel; Manjunath P Pai; Thomas G Rosano; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

5.  Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

Authors:  Keso Skhirtladze; Doris Hutschala; Tatjana Fleck; Florian Thalhammer; Marek Ehrlich; Thomas Vukovich; Markus Müller; Edda M Tschernko
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  Vancomycin pharmacokinetics in burn patients and intravenous drug abusers.

Authors:  M J Rybak; L M Albrecht; J R Berman; L H Warbasse; C K Svensson
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

7.  Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infection.

Authors:  Alexandra I Stavrakis; Jared A Niska; Jonathan H Shahbazian; Amanda H Loftin; Romela Irene Ramos; Fabrizio Billi; Kevin P Francis; Michael Otto; Nicholas M Bernthal; Daniel Z Uslan; Lloyd S Miller
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

8.  Factors impacting unbound vancomycin concentrations in neonates and young infants.

Authors:  Anne Smits; Steven Pauwels; Matthijs Oyaert; Nele Peersman; Isabel Spriet; Veroniek Saegeman; Karel Allegaert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-16       Impact factor: 3.267

9.  Factors impacting unbound vancomycin concentrations in different patient populations.

Authors:  Matthijs Oyaert; Isabel Spriet; Karel Allegaert; Anne Smits; Kim Vanstraelen; Nele Peersman; Joost Wauters; Jan Verhaegen; Pieter Vermeersch; Steven Pauwels
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

10.  Serum protein-binding characteristics of vancomycin.

Authors:  H Sun; E G Maderazo; A R Krusell
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.